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Background: Analyses from clinical outcome studies including CAPRIE, CURE,
CREDO, CLARITY-TIMI 28, and CHARISMA demonstrate that nonsmokers experi-
ence less or no benefit from clopidogrel (Clop) treatment as compared with smokers, who
have robust treatment benefit. Moreover, the efficacy of double dose clopidogrel was
confined to smokers in the PCI cohort of the CURRENT trial. However, there are no
prospective studies evaluating the effects of smoking status on Clop and prasugrel (Pras)
pharmacodynamics (PD).
Methods: PARADOX was a prospective, double-blind, placebo-controlled study of 56
nonsmokers and 54 smokers with stable CAD on aspirin therapy randomized to Clop (75
mg qd for 10 d) or Pras (10 mg qd for 10 d) and crossed-over after 14 d washout. The
co-primary objectives were PD of: 1) Clop nonsmokers vs. Clop smokers and 2) Clop
smokers vs. Pras smokers. PD was assessed using VerifyNow (VN)-P2Y12 assay and
VASP PRI.
Results: VN-P2Y12 % Inhibition and PRU results are shown in the Figure. VASP PRI
results were consistent with the VN-P2Y12 assay results.
Conclusions: PARADOX is the first prospective study to demonstrates that the
antiplatelet effect of Clop is less in nonsmokers than smokers whereas smoking status does
not influence the antiplatelet effect of Pras. Pras has significantly greater antiplatelet effects
than Clop regardless of smoking status. Clop nonsmokers demonstrate greater platelet
reactivity than any other group. The PD findings of PARADOX provide a mechanism to
explain the results of analyses from randomized trials demonstrating less or no clinical
benefit of Clop treatment in nonsmokers.
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Background: The clinical importance of adherence to the recommended duration of dual
antiplatelet therapy after coronary stent implantation is difficult to assess in real-life
settings, and limited data are available.
Methods: In Western Denmark, we followed 13,001 patients treated with bare metal
stent (BMS: n 8847) or drug-eluting stent (DES: n 4154) implantation between 2002
and 2005. We obtained 1-year data on clopidogrel prescription fillings and major cardiac
adverse cardiovascular events (MACE) by linkage of national registries. Dual antiplatelet
treatment with aspirin and clopidogrel was recommended for 1 year after stent implan-
tation by November 2002. MACE was defined as cardiac death, myocardial infarction, or
definite stent thrombosis.
Results: Discontinuation of clopidogrel was common in both the BMS and DES groups,
and 70%, 73%, and 73% used clopidogrel for more than 9 months in 2003, 2004, and
2005, respectively. Discontinuation of clopidogrel within the first 6 months was not
significantly associated with an increased risk of MACE after BMS implantation (3
month of treatment: hazard ratio (HR) 1.33, 95% confidence intervals (CI) 0.77-2.29;
3-6 months clopidogrel: HR  1.35, 95% CI 0.85-2.14), whereas clopidogrel discontin-
uation after DES implantation was associated with a higher rate of MACE (3 month of
treatment: HR  1.99, 95% CI 0.47-8.42; 3-6 months clopidogrel: HR  2.61, 95% CI
1.31-5.21). Discontinuation after 6 months was associated with a non-significant 37%
increased rate of MACE for BMS (HR  1.37, 95% CI 0.86-2.18), but not DES (HR 
0.95, 95% CI 0.50-1.82).
Conclusions: Discontinuation of clopidogrel was frequently encountered within the first
year after coronary stent implantation in spite of a general recommendation of clopidogrel
treatment for 1 year. Discontinuation of clopidogrel was, although non-significantly,
associated with a 35% increased rate of MACE within one year after BMS implantation.
In comparison, clopidogrel discontinuation after DES implantation was associated with a
markedly 2-fold increased HR, but only within the first 6 month after implantation.
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Background: Bleeding events after percutaneous coronary intervention (PCI) are
associated with increased risk of death at long-term follow-up. Increasing evidence
suggests that platelet reactivity (PR) may reliably predict bleeding. Aim of the present
study was to investigate the potential incremental value of PR in predicting bleeding
events in patients undergoing PCI via the femoral approach over a validated bleeding risk
score (BRS) of clinical and procedural variables (bleedingriskscore.org).
Methods: A total of 800 patients undergoing elective PCI via the femoral approach were
included in this study. PR was measured immediately before PCI with the VerifyNow
P2Y12 Assay. Calculation of the BRS included the following variables: age, gender, intra
aortic balloon pump, glycoprotein IIb/IIIa inhibitors, chronic kidney disease, anemia,
low-molecular-weight heparin within 48h pre-PCI. Bleeding events were monitored up to
30 days after PCI and defined according to the Thrombolysis in Myocardial Infarction
(TIMI), Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events
(REPLACE-2) and Bleeding Academic Research Consortium (BARC).
Results: A total of 28 (3.5%) TIMI, 44 (5.5%) BARC class 2 and 32 (4%)
REPLACE-2 bleedings occurred. Both RBS (area under the curve [AUC] 0.717 for TIMI,
0.733 for BARC class2 and 0.719 for REPLACE-2 bleedings), and PR (AUC 0.729 for
TIMI, 0.736 for BARC class 2 and 0.722 for REPLACE-2 bleedings) showed high
discriminatory power for bleeding events according to all definitions. However, when
combined together, they resulted in a significantly increased discriminatory power (TIMI:
AUC 0.818, p0.002 vs. RBS alone; BARC class 2: AUC 0.812, p0.002 vs. RBS
alone; REPLACE-2: AUC 0.813, p0.001 vs. RBS alone).
Conclusions: Platelet reactivity has incremental predictive value on bleeding events after
PCI via the femoral approach over a validated risk score of clinical and procedural
variables.
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